Table 5.
Area Under the Concentration-Time Curve for Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol in Children Treated for Tuberculosis, by Patient Characteristics
| Rifampicin | Isoniazid | Pyrazinamide | Ethambutol | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Patient Characteristic | Children Evaluated, No. | Coefficient (95% CI)a | P Value | Coefficient (95% CI)a | P Value | Coefficient (95% CI)a | P Value | Coefficient (95% CI)a | P Value |
| Sex | |||||||||
| Male | 40 | Referent | .88 | Referent | .67 | Referent | .63 | Referent | .62 |
| Female | 37 | 0.8 (− 9.3 to 10.9) | 1.2 (−4.4 to 6.8) | 20.2 (−63.0 to 103) | −1.1 (−5.7 to 3.5) | ||||
| HIV status | |||||||||
| Negative | 47 | Referent | .07 | Referent | .18 | Referent | .97 | Referent | .83 |
| Positive | 20 | −10.6 (−21.9 to .7) | −3.9 (−9.7 to 1.9) | −4.8 (226.5, 216.9) | −.9 (−9.9 to 8.1) | ||||
| WAZ | |||||||||
| Below −2 | 29 | Referent | .59 | Referent | .75 | Referent | .61 | Referent | .04 |
| ≥2 | 48 | 3.2 (−8.7 to 15.1) | −1.0 (−7.1 to 5.1) | 23.9 (−71.2 to 119) | 4.2 (.2–8.2) | ||||
| WHZ | |||||||||
| Below −2 | 52 | Referent | .56 | Referent | .87 | Referent | .54 | Referent | .52 |
| ≥2 | 8 | −5.5 (−24.2 to 13.2) | 1.0 (−11.0 to 13.0) | 52.4 (−120 to 226) | −2.2 (−9.4 to 5.0) | ||||
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; WAZ, weight-for-age z score; WHZ, weight-for-age z score.
aAdjusted for weight band.